Founded by four experts in laser physics, medical image analysis, and cranio-maxillofacial surgery, AOT is reinventing the bone surgery field with laser osteotomy technology: CARLO® (Cold Ablation Robotguided Laser Osteotome).
-
Interview with Braizon Therapeutics
Applying intelligently glycemic control and a systematic route through the BBB (blood-brain barrier) to effectively reach neurons. Venture Valuation (VV) interviewed the CEO, Mariko Tosu, PhD (more…)
-
Interviews with leading Life Sciences companies: ITO
ITO has developed, since its inception in 1916, high-end professional use therapeutic modalities as well as innovative personal use devices.
Venture Valuation (VV) interviewed the COO, Mayuko Ito, great-granddaughter of the founder Kenji Ito. -
Interviews with leading Life Sciences companies: Ava AG
Inspired by co-founder Lea von Bidder’s concept, the Ava bracelet is
becoming an indispensable device for women to monitor their own biological rhythms.
Venture Valuation (VV) interviewed Vicky Kummer, Global Brand Manager.Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
-
Interviews with leading Life Sciences companies: Innophys Co.
Invented by Prof. Hiroshi Kobayashi, Department of Mechanical Engineering, Tokyo University of Science, the Muscle Suit® is becoming an indispensable device for the elderly care services
as well as many other heavy lifting tasks. Venture Valuation (VV) interviewed Takashi Furukawa, CEO.Would you like to be notified about new reports and other valuable content published by Venture Valuation?
-
Interviews with leading Life Sciences companies: Megakaryon Corporation
Current transfusion medicine entirely relies on donated
blood. Megakaryon will change the transfusion practices by supplying
safe and cost-saving platelets produced in vitro. Mass production in
Japan is expected to begin in 2020. Venture Valuation (VV) interviewed Genjiro Miwa, CEO and Founder. -
Interviews with leading Life Sciences companies: tella inc.
Leveraging its proprietary technology of culturing highly purified dendritic cells (DCs), tella is developing, as its first immunotherapeutic product, a DC-based vaccine in combination with WT1 (Wilms’ tumor gene 1) antigen for inoperable pancreatic cancer. Venture Valuation (VV) interviewed Dr. Yuichiro Yazaki, President and CEO.
-
Interviews with leading Life Sciences companies: PeptiDream Inc.
Inventiveness in peptide drug technology and a well thought-
out business strategy characterize PeptiDream’s thriving growth.
Venture Valuation (VV) interviewed Kiichi Kubota, co-founder and
Chairman. -
Interviews with leading Life Sciences companies: GeNeuro SA
By leveraging expertise it has built up over decades in the HERV medical research and development, GeNeuro is engaging in unprecedented therapeutic development targeting HERVs. Venture Valuation (VV) interviewed Jesús Martin-Garcia, co-founder and CEO
-
Interviews with leading Life Sciences companies: ObsEva SA
ObsEva is specialized in re energizing women’s reproductive and pregnancy therapeutics that have been overlooked and underserved for years. Venture Valuation (VV) interviewed Dr. Ernest Loumaye, co-founder and CEO.
